clonidine has been researched along with Cognition Disorders in 13 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double blind, placebo controlled, randomized, yet balanced, cross-over experiment, 20 male schizophrenia patients on stable medication were assessed in an auditory prepulse inhibition (PPI), sensitization, and habituation of the startle reflex paradigm on 5 occasions: once after oral administration of placebo and after a single dose of 25, 50, 75, and 150 µg of clonidine." | 9.17 | Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication. ( Glenthøj, BY; Oranje, B, 2013) |
| "In a double blind, placebo controlled, randomized, yet balanced, cross-over experiment, 20 male schizophrenia patients on stable medication were assessed in an auditory prepulse inhibition (PPI), sensitization, and habituation of the startle reflex paradigm on 5 occasions: once after oral administration of placebo and after a single dose of 25, 50, 75, and 150 µg of clonidine." | 5.17 | Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication. ( Glenthøj, BY; Oranje, B, 2013) |
| "Our findings reveal that neuropathic pain-related cognitive impairments in male mice are correlated to bilateral morphological changes in PV interneurons and layer 5/6 IL pyramidal neuron AIS." | 1.48 | Neuropathic Pain Creates an Enduring Prefrontal Cortex Dysfunction Corrected by the Type II Diabetic Drug Metformin But Not by Gabapentin. ( Ahmad, A; Kroener, S; Mejia, G; Mwirigi, J; Pradhan, G; Price, T; Shiers, S, 2018) |
| " Chronic administration of low doses of the neurotoxin 1-methy,4-phenyl,1,2,3,6-tetrahydropyridine (MPTP) can induce cognitive dysfunction in non-human primates, including impaired performance on a variable delayed response (VDR) task with attentional and memory components." | 1.36 | Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism. ( Decamp, E; Schneider, JS; Tinker, JP, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 6 (46.15) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shiers, S | 1 |
| Pradhan, G | 1 |
| Mwirigi, J | 1 |
| Mejia, G | 1 |
| Ahmad, A | 1 |
| Kroener, S | 1 |
| Price, T | 1 |
| Jabaris, SS | 1 |
| Sumathy, H | 1 |
| Girish, R | 1 |
| Narayanan, S | 1 |
| Sugumar, M | 1 |
| Saravana Babu, C | 1 |
| Thanikachalam, S | 1 |
| Thanikachalam, M | 1 |
| Schneider, JS | 1 |
| Tinker, JP | 1 |
| Decamp, E | 1 |
| Hymel, KA | 1 |
| Sufka, KJ | 1 |
| Oranje, B | 1 |
| Glenthøj, BY | 1 |
| Moore, TL | 1 |
| Schettler, SP | 1 |
| Killiany, RJ | 1 |
| Herndon, JG | 1 |
| Luebke, JI | 1 |
| Moss, MB | 1 |
| Rosene, DL | 1 |
| Hunt, RD | 2 |
| Hoehn, R | 1 |
| Stephens, KJ | 1 |
| Riley, W | 1 |
| Osten, C | 1 |
| Moffoot, A | 1 |
| O'Carroll, RE | 1 |
| Murray, C | 1 |
| Dougall, N | 1 |
| Ebmeier, K | 1 |
| Goodwin, GM | 1 |
| Arnsten, AF | 2 |
| Steere, JC | 1 |
| Goldman-Rakic, PS | 1 |
| King, VL | 1 |
| Brooner, RK | 1 |
| Kidorf, MS | 1 |
| Stoller, KB | 1 |
| Mirsky, AF | 1 |
| Raskind, MA | 1 |
| Peskind, ER | 1 |
| Holmes, C | 1 |
| Goldstein, DS | 1 |
| Mair, RG | 1 |
| McEntee, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Metformin on Chronic Pain After Thoracic Surgery in Diabetic Patients[NCT04089813] | 200 participants (Anticipated) | Observational | 2019-09-10 | Not yet recruiting | |||
| A Single-blind, Randomised, Sham Controlled, Phase IIa Exploratory Clinical Trial, to Examine the Safety and Efficacy of BGX-3006 (tPCS) on Paediatric ADHD Participants.[NCT02323633] | Phase 2 | 48 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
| Differences by Sex and Genotype in the Effects of Stress on Executive Functions[NCT04273880] | Phase 1 | 146 participants (Anticipated) | Interventional | 2018-04-28 | Recruiting | ||
| Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates[NCT00865332] | 0 participants (Actual) | Observational | 2007-12-12 | Withdrawn | |||
| Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD)[NCT03710642] | Phase 2 | 35 participants (Actual) | Interventional | 2018-10-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The ADCS-ADL-Severe questionnaire is a secondary outcome measure aimed at detecting functional decline in people with severe AD. This scale is best suited for evaluating people with MMSE scores below 15/30, or equivalent. Questions are administered to a qualified caregiver informant about a set of 19 basic and instrumental ADL. Instrumental ADL are selected to be relevant to this level of severity of dementia, e.g., obtaining a beverage, turning lights on and off, turning a faucet on and off. Performance of each of these activities during the past 4 weeks, as well as the level of performance, are rated. A total score is derived by summing scores across items, and ranges from 0 (maximal impairment) to 54 (maximally independent function).~This outcome is the change from baseline to week 12." (NCT03710642)
Timeframe: 12 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Treatment (Prazosin) | -1.47055 |
| Placebo Oral Capsule | -4.53993 |
"The ADCS-CGIC-A is the primary outcome measure. It will be anchored to disruptive agitation, the target behaviors in this study. It measures whether the effects of active treatment are substantial enough to be detected by a skilled and experienced clinician on the basis of a direct examination of the participant and an interview of the participant's primary caregiver and other LTC facility staff. The baseline assessment is qualitative therefore there is no score at baseline; post-baseline scores represent a change score compared to baseline.~The ADCS-CGIC-A is a 7-point scale that is structured as the clinician's assessment of change from baseline compared to the ADCS-CGIC-A Baseline Worksheet. There is no baseline score; post-baseline scores range from 1 (improvement) to 7 (worsening). A score of 1-2 indicates clinically meaningful improvement; a score of 3-5 indicates no clinically meaningful change; a score of 6-7 indicates clinically meaningful worsening." (NCT03710642)
Timeframe: From Baseline through Week 12.
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Treatment (Prazosin) | 3.434 |
| Placebo Oral Capsule | 3.442 |
"Comparison of effects on caregiver distress/occupational disruptiveness scores on the NPI/NPI-NH. Minimum score is 0 and maximum score is 60. A higher score is a worse outcome.~This outcome is the change from baseline to week 12." (NCT03710642)
Timeframe: 12 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Treatment (Prazosin) | -2.4438 |
| Placebo Oral Capsule | 0.9446 |
"The NPI was designed to characterize the neuropsychiatric symptoms and psychopathology of patients with AD and other dementias residing in the community about which information was obtained from family caregivers. The content of the questions and their scoring in the NPI-NH are identical to those of the NPI except for some slight rephrasing to be consistent with the LTC environment where information is gathered from professional caregivers. Assessment of the impact of behavioral disturbances on family and professional caregivers, is assessed by a caregiver distress scale in the NPI and an occupational disruptiveness scale in the NPI-NH; scoring of this component remains identical. Minimum score is 0 and highest score is 144. A higher score means a worse outcome.~This outcome is the change from baseline to week 12." (NCT03710642)
Timeframe: 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Treatment (Prazosin) | -6.033 |
| Placebo Oral Capsule | 5.506 |
Cumulative total dose of Lorazepam rescue medication administered during the trial. Information on the total mg rescue lorazepam administered will be collected as additional secondary outcome measures. If prazosin is more effective than placebo, it is predicted that participants randomized to prazosin will be prescribed lower cumulative mg of rescue lorazepam for management of persistent or worsening disruptive agitation. (NCT03710642)
Timeframe: 12 weeks
| Intervention | mg (Mean) |
|---|---|
| Treatment (Prazosin) | 0.25 |
| Placebo Oral Capsule | 0.14 |
Comparison of proportions of responders versus non responders on the ADCS-CGIC-A. Responders are defined as those with moderate or marked improvement in agitation symptoms compared to baseline assessment. (NCT03710642)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Prazosin) | 7 |
| Placebo Oral Capsule | 1 |
Cox proportional hazard modelling comparing the median time to drop out between treatment groups. (NCT03710642)
Timeframe: 12 weeks
| Intervention | days (Median) |
|---|---|
| Treatment (Prazosin) | 65.63 |
| Placebo Oral Capsule | 54.62 |
2 reviews available for clonidine and Cognition Disorders
| Article | Year |
|---|---|
Clinical patterns of ADHD: a treatment model based on brain functioning.
Topics: Arousal; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Child, Pres | 1994 |
The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Animals; Attention Deficit Disorder with Hyperactivity; Clonidine; Cognit | 1996 |
3 trials available for clonidine and Cognition Disorders
| Article | Year |
|---|---|
Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication.
Topics: Acoustic Stimulation; Adrenergic alpha-2 Receptor Agonists; Adult; Blinking; Clonidine; Cognition Di | 2013 |
Clonidine infusion increases uptake of 99mTc-Exametazime in anterior cingulate cortex in Korsakoff's psychosis.
Topics: Adult; Aged; Alcohol Amnestic Disorder; Cerebrovascular Circulation; Clonidine; Cognition Disorders; | 1994 |
Cognitive enhancement in Korsakoff's psychosis by clonidine: a comparison with L-dopa and ephedrine.
Topics: Alcohol Amnestic Disorder; Attention; Biogenic Amines; Brain Chemistry; Clonidine; Cognition Disorde | 1986 |
8 other studies available for clonidine and Cognition Disorders
| Article | Year |
|---|---|
Neuropathic Pain Creates an Enduring Prefrontal Cortex Dysfunction Corrected by the Type II Diabetic Drug Metformin But Not by Gabapentin.
Topics: Analgesics; Animals; Attention; Axons; Clonidine; Cognition Disorders; Discrimination, Psychological | 2018 |
Phosphodiesterase-4 inhibitors ameliorates cognitive deficits in deoxycorticosterone acetate induced hypertensive rats via cAMP/CREB signaling system.
Topics: Adrenergic alpha-2 Receptor Agonists; Aminopyridines; Animals; Antihypertensive Agents; Benzamides; | 2015 |
Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism.
Topics: Adrenergic alpha-Agonists; Analysis of Variance; Animals; Attention; Clonidine; Cognition Disorders; | 2010 |
Pharmacological reversal of cognitive bias in the chick anxiety-depression model.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antidepressive Agents; Anxiety; Bias; Chickens; Clo | 2012 |
Cognitive impairment in aged rhesus monkeys associated with monoamine receptors in the prefrontal cortex.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Age Factors; Aging; Analysis of Variance; A | 2005 |
Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism.
Topics: Animals; Benzazepines; Clonidine; Cognition Disorders; Dopamine; Female; Haloperidol; Macaca mulatta | 1998 |
Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism.
Topics: Animals; Benzazepines; Clonidine; Cognition Disorders; Dopamine; Female; Haloperidol; Macaca mulatta | 1998 |
Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism.
Topics: Animals; Benzazepines; Clonidine; Cognition Disorders; Dopamine; Female; Haloperidol; Macaca mulatta | 1998 |
Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism.
Topics: Animals; Benzazepines; Clonidine; Cognition Disorders; Dopamine; Female; Haloperidol; Macaca mulatta | 1998 |
Attention deficit hyperactivity disorder and treatment outcome in opioid abusers entering treatment.
Topics: Adult; Ambulatory Care; Attention; Attention Deficit Disorder with Hyperactivity; Clonidine; Cogniti | 1999 |
Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Aged; Aging; Alzheimer Disease; Antimetabol | 1999 |